期刊
ANNUAL REVIEW OF MEDICINE, VOL 67
卷 67, 期 -, 页码 11-28出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-062913-051343
关键词
phosphoinositide 3-kinase (PI3K)/AKT; mammalian target of rapamycin (mTOR); pathway inhibitors; breast cancer; lymphoproliferative disorders; mutation
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据